Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of July 2021. The filing, dated July 12, 2021, incorporates by reference a press release issued on July 10, 2021 (Exhibit 99.1). The registrant is based in Mechelen, Belgium, and files annual reports on Form 20-F.
Financial Metrics
The provided filing text serves as a cover sheet and does not contain specific financial data. There is no information regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing does not disclose specific material changes to financial performance or operations. It solely references the issuance of a press release on July 10, 2021, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that the press release (Exhibit 99.1) contains a quote from Dr. Walid Abi-Saab, but the substance of this quote is not present in the source text.
Key Facts for Investor Verification
- Verify the content of the July 10, 2021 press release (Exhibit 99.1) to understand the material event triggering this filing.
- Confirm the identity of the registrant as Galapagos NV; the request metadata mentions "Lakefront Biotherapeutics NV," which does not appear in the filing text.
- Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing offerings.
- Note that this document is a procedural filing and does not contain standalone financial statements or operational metrics.